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Depression in Lung Cancer Patients: Role of Perceived Stigma 
Brian D. Gonzalez 
ABSTRACT 
Previous research suggests that lung cancer patients are at an increased risk for 
depressive symptomatology; however, little is known about the possible etiology or 
correlates of depression among these patients. This study examined the relationship 
between perceived stigma and depressive symptomatology among lung cancer patients, 
and sought to find potential mediators of this relationship. It was hypothesized that more 
perceived stigma would be related to greater depressive symptomatology and that 
perceived stigma would contribute unique variance to depressive symptomatology above 
and beyond that contributed by clinical, demographic, and psychosocial variables. A 
sample of 95 participants receiving chemotherapy for stage II-IV non-small cell lung 
cancer was recruited during routine outpatient chemotherapy visits. A medical chart 
review was conducted to assess clinical factors and participants completed a standard 
demographic questionnaire as well as measures of perceived stigma, depressive 
symptomatology, and other psychosocial variables. As hypothesized, there was a positive 
association of perceived stigma to depressive symptomatology. Perceived stigma 
contributed significant unique variance to depressive symptomatology. In addition dyadic 
adjustment and dysfunctional attitudes mediated this relationship. Future research should 
aim to replicate and extend these findings in longitudinal analyses and attempt to 
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ameliorate lung cancer patients’ depressive symptomatology by targeting perceived 
stigma.
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Introduction 
It is estimated that 215,020 people will be diagnosed with lung cancer in the 
United States in 2009 (Jemal et al., 2008). While early-stage lung cancer patients can 
sometimes be cured, many patients face bouts with lung cancer that can last several years 
and during which they may receive surgery, chemotherapy, radiation therapy, or all three. 
The effects of the illness and some of the side-effects of its treatment often make 
concealing one’s illness from others difficult, leaving lung cancer patients vulnerable to 
stigmatization. The potential contributory role of tobacco use to the development of lung 
cancer is another factor that may contribute to perceived stigmatization. Patients with this 
illness are at increased risk for depressive symptomatology, which itself is related to 
poorer quality of life among cancer patients (Hyodo et al., 1999; Montazeri, Milroy, 
Hole, McEwen, & Gillis, 1998; Turner, Muers, Haward, & Mulley, 2007; Visser & 
Smets, 1998). Some correlates of depressive symptomatology in lung cancer patients 
have been identified; however, the potential contribution of illness-related perceived 
stigma has yet to be examined. To address this issue, the current study seeks to determine 
whether perceived stigma is related to depressive symptomatology among lung cancer 
patients.  
Lung Cancer 
 Lung cancer is one of the most common and deadliest forms of cancer. It accounts 
for 15% of new cancer cases and 29% of cancer deaths annually (Jemal et al., 2008). It is 
the leading cause of cancer-related death in males (31%) and females (26%), far 
 2 
outnumbering the rates of deaths due to prostate cancer (10%) and breast cancer (15%) in 
males and females, respectively (Jemal et al., 2008). The discrepancy between the 
prevalence of lung cancer and the percentage of cancer-related deaths attributed to lung 
cancer is a testament to its lethality. This lethality is exacerbated by the late stage at 
which lung cancer is often detected, which is partly due to the less-than-optimal detection 
methods (e.g. chest x-rays); newer methods (e.g., spiral CT scans) remain controversial 
(Kaneko et al., 1996). In addition, doctors may have difficulty differentiating symptoms 
of lung cancer from similar smoking-related problems, which may be another factor 
contributing to the late stage in which lung cancer is often detected. For example, in a 
recent qualitative study, lung cancer patients reported that their disease-related symptoms 
were often ignored by medical doctors, sometimes for several years, and attributed 
instead to “smoker’s cough” (Chapple, Ziebland, & McPherson, 2004).  
Depression in Lung Cancer Patients 
Lung cancer patients often report experiencing symptoms such as fatigue, 
insomnia, pain, and depression (Degner & Sloan, 1995; Sarna, 1993; Sarna, 1998). 
Several studies of lung cancer patients have found high rates of clinically significant 
depressive symptomatology shortly after diagnosis. For example, in a study of patients in 
Japan who had recently received a lung cancer diagnosis, 31% exhibited clinically 
significant levels of depressive symptomatology (Hyodo et al., 1999). Similarly, a study 
of lung cancer patients in Scotland found that 23% endorsed clinically significant 
depressive symptomatology when they were informed of their diagnosis (Montazeri et 
al., 1998). Additionally, a study of lung cancer patients in Britain about to receive 
radiotherapy found a 21% rate of clinically significant depressive symptomatology 
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(Turner et al., 2007). Hopwood and Stephens (2000) sampled lung cancer patients 
recruited into palliative therapy medication trials throughout the United Kingdom and 
reported a pre-treatment rate of clinically significant depressive symptomatology of 33%. 
The highest reported rate of depressive symptomatology is 44%, reported in a study of 
lung cancer patients referred to an Italian specialist center (Buccheri, 1998).   
Some evidence suggests that depressive symptomatology in lung cancer patients 
may remain elevated after treatment completion . For example, a postoperative study of 
lung cancer patients who had smoked within months of surgery reported a 29% rate of 
clinically significant depressive symptomatology (Walker, Zona, & Fisher, 2006). 
Hopwood and Stephens (2000) reported that 29% of lung cancer patients assessed 
between three and eight weeks after treatment had clinically significant depressive 
symptomatology. Rates of depressive symptomatology were 34% and 44% in two studies 
that assessed symptoms three months after the beginning of lung cancer treatment 
(Montazeri et al., 1998; Nakaya et al., 2006). In addition, a study of elderly lung cancer 
patients found that rates of clinically significant depressive symptomatology decreased 
only slightly from 39% at one month after the beginning of treatment to 31% more than 
one year later (Kurtz, Kurtz, Stommel, Given, & Given, 2002). The rates of depressive 
symptomatology in lung cancer patients exceed those reported by individuals with other 
types of cancer. For example, a sample of patients with breast cancer, head and neck 
cancer, and lymphoma reported an 8% rate of elevated depressive symptomatology 
(Berard, Boermeester, & Viljoen, 1998), and a sample of thyroid cancer patients reported 
a 17% rate (Tagay et al., 2006). 
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Correlates of Depression in Lung Cancer Patients 
Demographic Factors. Research on demographic correlates of depression in lung 
cancer patients is limited and results are mixed. For example, two studies of lung cancer 
patients have found women to be at higher risk of elevated depressive symptomatology 
than men (Hopwood & Stephens, 2000; Hyodo et al., 1999), but three other studies found 
no sex differences (Montazeri et al., 1998; Nakaya et al., 2006; Uchitomi et al., 2003). 
Similarly, three studies reported that older lung cancer patients were more likely to 
experience elevated depressive symptomatology compared to younger patients (Hyodo et 
al., 1999; Walker, Zona, Larsen, & Fisher, 2004; Walker et al., 2006); however, three 
other studies found no age differences (Montazeri et al., 1998; Nakaya et al., 2006; 
Uchitomi et al., 2003). One study found that years of education was negatively related to 
depressive symptomatology in lung cancer patients (Uchitomi et al., 2003); however, two 
other studies found no relationship for education (Montazeri et al., 1998; Nakaya et al., 
2006). Neither income nor marital status has been found to be related to depressive 
symptomatology among lung cancer patients (Montazeri et al., 1998; Nakaya et al., 2006; 
Uchitomi et al., 2003). Although female gender, older age, and fewer years of education 
may be positively related to depressive symptomatology in lung cancer patients, more 
research is needed to clarify these relationships. 
Clinical Factors. More definitive conclusions can be made about the 
relationships between clinical factors and depressive symptomatology in lung cancer 
patients, in part because there is more research in this area. Clinical factors studied 
include performance status (i.e., clinical ratings of overall physical functioning), disease 
stage, type of cancer treatment, functional impairment, and symptom severity. Studies 
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have consistently found that poorer performance status is related to greater depressive 
symptomatology (Hopwood & Stephens, 2000; Hyodo et al., 1999; Nakaya et al., 2006; 
Uchitomi et al., 2003; Walker et al., 2006). Several studies have reported no relationship 
between disease stage and depressive symptomatology in lung cancer patients before 
treatment (Montazeri et al., 1998; Nakaya et al., 2006) and as shortly as a few weeks and 
as long as 12 months after treatment initiation (Montazeri et al., 1998; Uchitomi et al., 
2003; Walker et al., 2006). However, one study found that two weeks after the diagnosis 
of lung cancer, patients with later disease stages exhibited less depressive 
symptomatology than those with earlier disease stages (Hyodo et al., 1999). Only two 
studies have examined whether depressive symptomatology varies as a function of lung 
cancer treatment type. While Montazeri and colleagues (1998) found no relationship 
between type of treatment and depressive symptomatology, Hyodo and colleagues (1999) 
reported that patients who had not received radiotherapy were more depressed than 
patients who had radiotherapy. Greater functional impairment (Hopwood & Stephens, 
2000) and symptom severity (Hopwood & Stephens, 2000; Kurtz et al., 2002) have been 
found to be positively related to greater depressive symptomatology; however, these 
findings require further replication.  
Psychosocial Factors. The psychosocial correlates of depressive symptomatology 
in lung cancer patients have only recently begun to be studied. Less adaptive coping (i.e., 
less problem-focused coping) was found to be related to greater depressive 
symptomatology in a sample of lung cancer patients who had recently undergone surgical 
resection and had smoked within three months before surgery (Walker et al., 2006). In 
addition, two aspects of greater social support have been found to be related to less 
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depressive symptomatology among lung cancer patients (Fisher Jr, La Greca, Greco, 
Arfken, & Schneiderman, 1997). In separate studies of postoperative lung cancer 
patients, nondirective emotional support (i.e., emotionally assisting or cooperating with 
the patient while allowing the responsibility for behavior and choices to remain with the 
patient) was associated with less depressive symptomatology, while directive 
instrumental support (i.e., support that takes responsibility for financial and material 
matters) was associated with more depressive symptomatology (Walker, Larsen, Zona, 
Govindan, & Fisher, 2004; Walker et al., 2006). Thus, emerging evidence suggests that 
coping and social support merit further study as psychosocial correlates of depressive 
symptomatology in lung cancer patients.  
Smoking Behavior. To date, only three studies have investigated the relationship 
between smoking status and depressive symptomatology in lung cancer patients. One 
study assessed smoking status before curative resection of non-small cell lung cancer 
(NSCLC) and examined its relationship to depressive symptomatology one year later; no 
relationship was evident (Uchitomi et al., 2003). In another study of NSCLC patients, no 
relationship was found between preoperative smoking status and depressive 
symptomatology assessed three months after surgery (Nakaya et al., 2006). In a third 
study of patients who had smoked within the three months before lung cancer resection, 
there was a trend towards a relationship between postoperative smoking status and 
depressive symptomatology, such that those who continued smoking after surgery had 
higher depressive symptomatology than those who had quit (Walker et al., 2004). 
Although all three studies reported no significant relationship between depression and 
smoking status, the evidence of such a relationship in the general population (Goodman 
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& Capitman, 2000) and the potential implications it would carry if a similar relationship 
were found among lung cancer patients argue for additional research on this topic.  
Stigma in Lung Cancer Patients 
An important factor that might be related to differences in depressive 
symptomatology among lung cancer patients is perceived stigma. Modified Labeling 
Theory, which was first used to describe the effects of stigma on individuals with 
psychiatric disorders (Link, Cullen, Struening, Shrout, & Dohrenwend, 1989), posits that 
once society labels an individual, they are subject to uniform responses from others. 
These societal responses can constrain an individual into the role to which they are being 
subjected, which can cause the individual to accept this role and incorporate it into their 
identity. This process can often result in psychological harm. Perceived stigma, the 
perception that one is subject to the uniform responses from others that are to be expected 
for an individual with a certain label, has been studied in chronically-ill populations, 
primarily with HIV-positive patients and those infected with Hepatitis C. Individuals with 
these illnesses often perceive (accurately or inaccurately) that they are undergoing 
uniform responses from society that are a result of their label (e.g., HIV positive). The 
potential for stigma originates from the fact that these diseases are often transmitted via 
unsafe sexual behavior and intravenous drug use (Beyrer et al., 2005; Purcell, Parsons, 
Halkitis, Mizuno, & Woods, 2001).  
Research has examined the relationship of perceived stigma to depressive 
symptomatology in HIV positive individuals (Berger, Ferrans, & Lashley, 2001; Miles, 
Burchinal, Holditch-Davis, Wasilewski, & Christian, 1997; Simbayi et al., 2007). One 
such study sampled HIV positive individuals in South Africa and examined several 
 8 
potential demographic and psychosocial correlates (Simbayi et al., 2007). In addition to 
finding a significant positive relationship between internalized stigma and depressive 
symptomatology, this study also found that internalized stigma contributed unique 
variance to depressive symptomatology over and above demographic factors (i.e., sex, 
age, race, drugs and alcohol intake), clinical factors (i.e., taking HIV medications, 
presence of HIV-related symptoms), and social support (Simbayi et al., 2007). Similar 
findings were reported in a study of patients with the Hepatitis C virus visiting a clinic in 
Iowa (Zickmund, Masuda, Ippolito, & LaBrecque, 2003). Findings indicated that a 
majority of participants believed they had been stigmatized due to their illness and 
consequently reported greater depressive symptomatology than those who did not 
perceive stigmatization (Zickmund et al., 2003). 
 Similarly, lung cancer patients are likely to experience stigma as a function of 
their disease because a particular behavior, smoking, is strongly associated with lung 
cancer incidence. Smoking is estimated to cause about 90% of all lung cancer cases 
(Godtfredsen, Prescott, & Osler, 2005). Because it is an often preventable disease, 
patients and others may often blame the patient for their lung cancer diagnosis. To date, 
research on perceived stigma in lung cancer patients is limited. One of the key pieces of 
evidence is a qualitative study conducted by Chapple and colleagues (2004). In this 
study, lung cancer patients in the United Kingdom were interviewed about their personal 
history with the disease. A common theme reported by many patients involved feeling 
stigmatized because of the strong association between smoking and lung cancer (Chapple 
et al., 2004). Whereas patients suffering from other cancers (e.g., breast, prostate) may 
not necessarily be blamed for their disease, these lung cancer patients reported feeling 
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blamed for their disease by friends, loved ones, and even healthcare professionals 
(Chapple et al., 2004). Moreover, even patients who reported no history of smoking or 
had stopped smoking several years before their diagnosis reported that they felt blamed 
for their illness (Chapple et al., 2004). Perceived stigma may be related to depressive 
symptomatology in lung cancer patients, as is the case for patients with Hepatitis C 
((Zickmund et al., 2003) and HIV (Berger et al., 2001; Miles et al., 1997; Simbayi et al., 
2007); however, a search of the published literature suggests that this hypothesis has yet 
to be tested. 
Dyadic Adjustment and Dysfunctional Attitudes 
In studying the relationship of stigma to depressive symptomatology in lung 
cancer patients, it will be important to determine whether stigma accounts for variability 
in depression distinct from other psychosocial variables often found to be associated with 
depression. Dyadic adjustment (a measure of relational satisfaction) and dysfunctional 
attitudes (a measure of cognitive vulnerability to depression) may be related to depressive 
symptomatology in lung cancer patients, but these relationships have yet to be studied. 
However, an association between poorer dyadic adjustment and greater depressive 
symptomatology has been shown in studies of healthy populations (Herr, Hammen, & 
Brennan, 2007; Jenewein et al., 2008; King & Arnett, 2005; Lewis, Fletcher, Cochrane, 
& Fann, 2008; Whisman, 2007) as well as in medically-ill populations (Brotto et al., 
2008; King & Arnett, 2005). For example, a study of outpatient multiple sclerosis 
patients and their significant others reported a relationship between poorer dyadic 
adjustment and greater depressive symptomatology (King & Arnett, 2005). In addition, a 
trial of a psycho-educational intervention aimed to reduce Female Sexual Arousal 
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Disorder symptoms in gynecologic cancer patients reported a relationship between poorer 
dyadic adjustment and greater depressive symptomatology (Brotto et al., 2008).  
Similarly, there is evidence for a relationship of dysfunctional attitudes to 
depressive symptomatology in other populations. In a study of women with and without a 
history of depression, more dysfunctional attitudes were associated with a greater number 
of previous episodes of depression and greater likelihood to have a future depressive 
episode (Otto et al., 2007). Also, in a sample of college undergraduates with and without 
a history of depression, more dysfunctional attitudes were found to be related to greater 
depressive symptomatology (Haffel et al., 2005). The relationships between dyadic 
adjustment, dysfunctional attitudes, and depressive symptomatology merit exploration in 
lung cancer patient populations. 
Aims 
The primary aim of this study was to examine the relationship between stigma, as 
measured by the Social Impact Scale (SIS; Fife & Wright, 2000), and depressive 
symptomatology, as measured by the Center for Epidemiological Studies Depression 
Scale (CES-D; Radloff, 1977), in people with lung cancer. The study also aimed to 
examine relationships between several psychosocial factors found to be related to 
depression in other populations (i.e., coping, social support, dyadic adjustment, and 
dysfunctional attitudes) and depressive symptomatology in lung cancer patients. 
Additionally, this study aimed to determine which demographic and clinical factors are 
related to perceived stigma. Finally, this study also sought to determine if stigma 
accounts for variability in depressive symptomatology in lung cancer patients above and 
beyond psychosocial factors found to be related to depressive symptomatology in other 
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populations, and if psychosocial factors mediate the relationship between perceived 
stigma and depressive symptomatology.  
Hypotheses 
1. It was hypothesized that greater perceived stigma would be related to greater 
depressive symptomatology. 
2. Also, it was hypothesized that more avoidant coping, poorer social support, 
poorer dyadic adjustment, and more dysfunctional attitudes would be related to 
greater depressive symptomatology. 
3. In addition, it was hypothesized that perceived stigma would explain unique 
variance in depression over and above that explained by other psychosocial, 
demographic, and clinical variables related to depressive symptomatology.  
4. Finally, further analyses were conducted, based on the result of hypothesis testing, 
to determine if psychosocial factors mediated the relationship between perceived 
stigma and depressive symptomatology.  
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Method 
Participants 
 Eligibility criteria for the current study were: 1) receiving chemotherapy for stage 
II, III, or IV non-small cell lung cancer 2) ≥ 18 years of age, 3) able to understand, speak, 
and read English, 4) no history of other cancers with the exception of non-melanoma skin 
cancer, 5) and able to provide informed consent.  
Procedure 
Study eligibility was determined via consultation with H. Lee Moffitt Cancer 
Center Thoracic Oncology Program team members. Potential participants were 
approached during a routine outpatient visit and had the study protocol explained. Those 
eligible and interested provided written informed consent. Participants were given the 
option of filling out the study measures during their outpatient visit or taking them home 
and returning the completed measures in a self-addressed stamped envelope that was 
provided. Participants were not compensated for their study participation.  
Measures 
 Demographics and Background Information. Demographics and background 
information were collected using a standardized self-report form. The variables assessed 
were: age, sex, race, ethnicity, education, income, marital status, and employment status. 
In addition, participants’ current and past smoking status, number of cigarettes smoked 
per day, and years of smoking were assessed. 
 Clinical Information. The following clinical information was assessed via a 
review of patients’ medical records: date of lung cancer diagnosis, disease stage, previous 
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lung cancer treatment, planned lung cancer treatment, and ECOG performance status 
(Oken et al., 1982).  
 Stigma. Experienced stigma was assessed using the Social Impact Scale (SIS; 
Fife & Wright, 2000), a 24-item Likert-type scale which measures the extent to which 
individuals with an illness believe they are experiencing social rejection, financial 
insecurity, internalized shame, and social isolation as a result of their illness. In addition 
to a total score, the measure yields subscale scores for the four aspects of experienced 
stigma described above. These four subscales have been shown to have strong internal 
consistency reliability (α range: .85 - .90), and though they are related, their relatively 
low zero-order correlations with one another (r range: .28 – .66) suggest that they assess 
divergent aspects of one’s illness-related stigma (Fife & Wright, 2000).  In the current 
study, analyses focused on the total score. 
 Dyadic Adjustment. Among participants who were living with a spouse or 
partner, relational adjustment was assessed using the Dyadic Adjustment Scale-4 (DAS-
4;  Sabourin, Valois, & Lussier, 2005), a Likert-type instrument designed for use with 
married, unmarried, and same-sex cohabitating couples. It is comprised of 4 items: “How 
often do you discuss or have you discussed divorce, separation, or terminating your 
relationship?”; “In general, how often do you think that things between you and your 
partner are going well?”; “Do you confide in your mate?”; and “Please circle the choice 
which best describes the degree of happiness, all things considered, of your relationship.” 
The DAS-4 has been shown to have adequate convergent and divergent validity, and a 
cut-off score of 13 has been posited as optimal for distinguishing between individuals 
with dyadic distress and those without (Sabourin et al., 2005). 
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Coping. Coping strategies were assessed using the Coping Responses Inventory 
(CRI; Moos, 1993), a 48-item Likert-type instrument which assesses specific coping 
responses via eight subscales. Four subscales assess approach coping styles; two are 
considered behavioral approach coping styles (seeking guidance and support, problem 
solving), and two are considered cognitive approach coping styles (logical analysis, 
positive reappraisal) (Moos, 1993). Four subscales assess avoidant coping styles; two are 
considered behavioral avoidant coping styles (seeking alternative rewards, emotional 
discharge), and two are considered cognitive avoidant coping styles (cognitive avoidance, 
acceptance or resignation) (Moos, 1993). The approach and avoidant scales of the CRI 
have been shown to have adequate internal consistency reliability (α’s = .74 and .66, 
respectively) in a sample of breast cancer patients (Hack & Degner, 2004). The eight 
individual subscales of the CRI have been validated (Moos, 1993) and been shown to 
have adequate internal consistency reliability (α range: .61 - .74) in a sample of ovarian 
cancer patients (Chan, Ng, Lee, Ngan, & Wong, 2003). In the present study, analyses 
focused on the cognitive avoidance subscale. 
Social Support. Social support was assessed using the ENRICHD Social Support 
Instrument (ESSI; Mitchell et al., 2003), a 5-item Likert-type instrument designed to 
assess emotional support. The ESSI has been shown to have strong internal consistency 
reliability (α = .87), good convergent validity with another measure of social support (r = 
.62), and relatively weak correlations with measures of structural and tangible support (r 
range: .20 - .25), which is indicative of divergent validity between emotional and other 
types of social support (Mitchell et al., 2003). Sample questions include “Is there 
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someone available to give you good advice about a problem?” and “Is there someone 
available to you who shows you love and affection?” (Mitchell et al., 2003).  
 Dysfunctional Attitudes. Dysfunctional attitudes were assessed via the 
Dysfunctional Attitudes Scale (DAS; Weissman & Beck, 1978), a 40-item Likert-type 
self-report measure of cognitive distortions. Participants will report, on a 1 to 7 scale, the 
degree to which they agree or disagree with items such as, “If a person asks for help, it is 
a sign of weakness.” In addition to face validity, the DAS has demonstrated concurrent 
validity with a measure of depressive symptomatology, including the ability to 
distinguish between depressed and non-depressed individuals. The DAS also has good 
internal consistency reliability (α range: .84 - .92) and test-retest reliability (r range: .80 – 
.84; Weissman & Beck, 1978). 
Depressive Symptomatology. Participants’ depressive symptomatology was 
assessed using the Center for Epidemiological Studies Depression Scale (CES-D; 
Radloff, 1977), a 20-item Likert-type self-report measure of depressive symptomatology. 
Participants answered questions about how they felt over the past week. Sample 
questions include, “I had trouble keeping my mind on what I was doing” and “I had 
crying spells.” Because it is brief and its queries focus primarily on cognitive and 
affective symptoms of depression rather than somatic symptoms, it is well-suited for use 
with the medically-ill, such as lung cancer patients (Hann, Winter, & Jacobsen, 1999). 
The CES-D has been shown to be a valid measure of depressive symptomatology with 
excellent internal consistency reliability, as well as adequate test-retest reliability in a 
sample of cancer patients (Hann et al., 1999).  
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History of Depression. Participants’ history of Major Depressive Disorder 
(MDD) prior to their lung cancer diagnosis was assessed using the Structured Clinical 
Interview for DSM-IV (SCID; Gibbon & Williams, 2002). The SCID is a widely-used 
structured interview which is used to determine diagnoses of numerous mental disorders 
according to Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV; 
(American Psychiatric Association, 2000) criteria. Good inter-rater agreement on 
diagnoses of MDD (κ = .80; Zanarini et al., 2000) has been demonstrated using trained 
raters. The mood episodes section of the SCID was administered by trained and 
periodically-observed staff to assess lifetime history of MDD prior to the participant’s 
date of diagnosis of lung cancer.  
Statistical Analyses 
 To test the study hypotheses, correlational analyses were conducted to determine 
the relationships between depressive symptomatology and each of the following: 
perceived stigma, social support, avoidant coping responses, and dysfunctional attitudes. 
A correlational analysis was also conducted to determine the relationship between 
depressive symptomatology and dyadic adjustment among the subset of participants who 
were living with a spouse or partner and were thus able to complete the measure 
assessing dyadic adjustment. 
 In addition, independent samples t-tests, ANOVAs, and chi-square tests were 
performed, as appropriate, to examine relationships between demographic and clinical 
variables and depressive symptomatology. 
Two hierarchical regression analyses were conducted to determine whether 
perceived stigma accounts for unique variance in depressive symptomatology not 
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accounted for by other psychosocial variables and by demographic, clinical, and smoking 
variables related to depressive symptomatology. In the first hierarchical regression 
analysis, depressive symptomatology was the dependent variable, and independent 
variables were included in the model in the following 4 steps: 
1. Presence of a lifetime (before lung cancer diagnosis) history of depression 
2. Any demographic, clinical, or smoking variable related to depressive 
symptomatology 
3. Social support, coping responses, and dysfunctional thoughts, regardless of 
the significance of their relationship to depressive symptomatology 
4. Perceived stigma 
In the second hierarchical regression analysis, dyadic adjustment was added as an 
independent variable in step 3. This analysis was conducted with the subset of 
participants who were living with a spouse or partner and were able to complete the 
DAS-4. 
Four additional hierarchical regression analyses were conducted to determine 
which components of perceived stigma contributed unique variance to depressive 
symptomatology. In these analyses, the four subscales of the Social Impact Scale were 
added as the independent variable in step 4. 
 In addition, independent samples t-tests, ANOVAs, and chi-square tests were 
performed, as appropriate, to examine relationships between demographic and clinical 
variables and perceived stigma. 
Finally, mediational analyses were conducted to determine whether social 
support, dyadic adjustment, coping styles, or dysfunctional attitudes mediated the 
 relationship between perceived stigma and depressive symptomatology. These analyses 
followed the established protocol for determining mediation (MacKinnon, Fairchild, & 
Fritz, 2007). MacKinnon, et al. (2007) lay out the following steps (see Figure 1):  
1. The dependent variable (depressive symptomatology) is regressed on the 
predictor (perceived stigma). The regression coefficient for the independent 
variable (IV) in this equation is termed c.  
2. The proposed mediator (psychosocial factor) is regressed on the predictor.  
The regression coefficient for the IV in this equation is termed a. 
3. The dependent variable is regressed on the predictor and mediator. The 
regression coefficient for the mediator is termed b, and the new regression 
coefficient for the predictor in this equation is termed c’. 
 
X 
b 
c (c’) X 
M a 
 
 
 
 
 
Figure 1. Path diagram for the indirect effect of a predictor on a dependent variable 
through a mediator. 
In order to satisfy the requirements for mediation, c, a, and b must be significant. 
Also, the decrease from c to c’ (indirect effect) must be significant as tested by the Sobel 
test. The Sobel test divides the value of the indirect effect by its standard error and 
compares the result to a standard normal distribution (Sobel, 1982). 
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A power analysis using Power and Precision 2.0 (Biostat, 2000) indicated that for 
a correlational analysis with a Type I error rate of .05 (two-tailed), the sample size of the 
current study (N = 95) would yield power equal to .85 for detecting a medium-sized 
effect (r = .30). A second analysis was conducted to determine the power of the 
hierarchical multiple linear regression model described above. It indicated that a model in 
which Step 1 (i.e., past history of depression) accounts for 10% of the variance in 
depressive symptomatology, Step 2 (i.e., demographic and clinical variables) accounts for 
an additional 10% of the variance, Step 3 (i.e., psychosocial variables) accounts for an 
additional 20% of the variance, power is equal to .82 with a Type I error rate of .05 and 
95 participants for detecting a 5% increase in variance accounted for by stigma on Step 4. 
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Results 
Participants 
 Eight hundred thirty-nine participants were screened for this study; of these, 680 
were ineligible based on medical record reviews (e.g., history of other cancer, not 
receiving chemotherapy). The remaining 159 participants were approached for 
participation; of these, an additional 17 were deemed ineligible before consent, 33 
refused to participate, and 109 agreed to participate (77% of those eligible). Of those who 
agreed to participate, 4 withdrew from the study, 4 never completed the study measures 
and could not be reached, and 6 were found to be ineligible after they participated. Thus, 
analyses were conducted on the 95 participants who had evaluable data, 66 of whom 
were living with a spouse/partner and were included in the sub-analyses with dyadic 
adjustment (See Figure 2 for a participant flow chart). The 109 patients who agreed to 
participate in the study did not differ in terms of age, gender, or race from the 33 patients 
who declined to participate, ps ≥ .48. 
   Assessed for eligibility 
(n= 839)       
 
Ineligible for participation 
(n = 680) 
 
 
Approached for consent 
(n = 159)  
 
21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Participant Flow Chart 
Consented 
(n = 109) 
Completed study measures 
(n = 95) 
Refused to participate 
(n = 33) 
Ineligible before consent 
(n = 17) 
Ineligible after consent 
(n = 6) 
Withdrew from study 
(n = 4) 
Failed to complete measures 
(n = 4) 
Living with spouse/partner 
(n = 66) 
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 Participants ranged in age from 42 to 83 years (M = 64.04; SD = 8.79). The 
majority of the participants were high school graduates (60%), married (61.1%), and 
White (92.6%). Mean Body Mass Index for this sample was 26.44 (SD = 5.18), which 
indicates that the average participant was slightly overweight. On average, participants 
were 18.14 months (SD = 30.35) from their original lung cancer diagnosis. Forty-five 
(47.4%) participants had surgery for this cancer and 41 (43.2%) had been treated with 
radiation therapy. The possible range of scores on the CES-D is from 0 to 60. The range 
of scores for this sample was 0 to 44. The mean CES-D score was 14.39 (SD = 8.26), and 
38% of participants (n = 36) met the CES-D cutoff for clinically significant depressive 
symptoms (≥16). Thirteen participants (13.7%) met criteria for a diagnosis of Past Major 
Depressive Disorder, and 16 (16.8%) were taking antidepressant medications at the time 
of the study visit. Twelve participants (12.6%) were never smokers, 68 (71.6%) were past 
smokers, and 15 (15.8%) were current smokers at the time of the study visit (see Tables 1 
and 2 for complete demographic and clinical information). All measures had adequate 
internal consistency reliability, (Cronbach’s alphas ≥ .72; see Table 3 for descriptive 
statistics and internal consistency reliabilities for each measure). 
 Table 1 
Demographic Characteristics of the Sample (N = 95)  
 
Variable M SD 
 
Age, years 64.04 (8.79) 
 
Pack Yearsa 35.43 (23.70) 
 
Variable n % 
 
Gender 
  Males 39 (41.1%) 
  Females 56 (58.9%) 
 
Education  
  ≤  High school graduate     38  (40.0%) 
  >  High school graduate 57  (60.0%) 
 
Race 
  White 88  (92.6%) 
  Non-White 7  (7.4%) 
 
Ethnicity 
  Hispanic 3  (3.2%) 
  Non-Hispanic      92 (96.8%) 
 
Marital Status 
  Currently Married      58  (61.1%) 
  Not Married       37  (38.9%)  
 
Total household income 
  < $ 40,000 22 (23.2%) 
  ≥ $40,000 44  (46.3%) 
  Declined to answer 29 (30.5%) 
 
Alcohol use in past month 
 No 42 (44.2%) 
 Yes 53 (55.8%) 
 
Cigarette use 
 Never 12 (12.6%) 
 Previous 68 (71.6%) 
 Current 15 (15.8%) 
 
aAmong only past smokers and current smokers (n = 83). 
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Table 2 
Clinical Characteristics of the Sample (N = 95) 
 
Variable M SD 
 
Body Mass Index 26.44 (5.18) 
 
Months Since Original Diagnosis 18.14 (30.35) 
 
Variable n % 
 
Disease Stage 
 II 3 (3.2%) 
 III 29 (30.5%) 
 IV 63 (66.3%) 
 
ECOG Performance Status 
 0 20 (21.0%) 
 1 62 (65.3%) 
 2 – 3 13 (13.7%) 
 
Diagnosis of Past Major Depression 
   No 82 (86.3%) 
   Yes 13 (13.7%) 
 
Taking antidepressant medication at time of study visit 
  No 79 (83.2%) 
  Yes 16 (16.8%) 
 
Had Surgery for This Cancer 
  No 50 (52.6%) 
  Yes 45 (47.4%) 
 
Had Radiation Therapy for This Cancer  
  Never 54 (56.9%) 
  Before current course of chemo 33 (34.7%) 
  Currently 8 (8.4%) 
 
Note: ECOG = Eastern Cooperative Oncology Group.
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 Table 3 
Mean, Standard Deviations, and Internal Consistency Reliabilities of Psychosocial 
Scales 
Scale M SD α 
Social Impact Scale 42.90 11.87 .95 
Dyadic Adjustment Scale 16.94 3.55 .83 
ENRICHD Social Support Instrument 22.74 3.04 .91 
CRI – Cognitive Avoidance 7.85 3.94 .72 
Dysfunctional Attitudes Scale 103.62 25.92 .89 
CES-D 14.39 8.26 .84 
Note: CRI = Coping Responses Inventory; CES-D = Center for Epidemiologic Studies 
Depression Scale. 
 
Relationship of Perceived Stigma and Depressive Symptomatology 
  Correlational analyses were conducted to test the hypothesis that perceived 
stigma would be would be positively related to depressive symptomatology (see Table 4). 
As hypothesized, these correlations indicate that more social rejection, financial 
insecurity, internalized shame, social isolation, and greater overall perceived stigma as a 
result of one’s lung cancer diagnosis were significantly related to greater depressive 
symptomatology. 
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 Table 4 
Correlations Between Depressive Symptomatology and Perceived Stigma (N = 95) 
Variable Depression (CES-D) p-value 
Perceived Stigma (SIS Total) .46 < .001 
Social Rejection (SocRej) .29  .004 
Financial Insecurity (FinIns) .43 < .001 
Internalized Shame (IntSha) .27 .010 
Social Isolation (SocIso) .58 < .001  
Note: CES-D = Center for Epidemiologic Studies Depression Scale; SIS = Social Impact 
Scale. 
Relationships of Other Psychosocial Variables with Depressive Symptomatology 
 A second set of correlational analyses was conducted to test the hypotheses that 
poorer social support, poorer dyadic adjustment, more avoidant coping, and more 
dysfunctional attitudes would be related to depressive symptomatology (see Table 5). As 
hypothesized, these correlations indicate that poorer social support, poorer dyadic 
adjustment, more avoidant coping, and more dysfunctional attitudes were significantly 
related to greater depressive symptomatology. 
26 
 Table 5 
Correlations Between Depressive Symptomatology and Psychosocial Variables (N = 95) 
Variable Depression (CES-D) p-value 
Social Support (ESSI) -.33  .001 
Dyadic Adjustment (DAS-4)a -.48 < .001 
Avoidant Coping (CRI CA) .36 < .001 
Dysfunctional Attitudes (DAS) .48 < .001 
Note: CES-D = Center for Epidemiologic Studies Depression Scale; ESSI = ENRICHD 
Social Support Instrument; DAS-4 = Dyadic Adjustment Scale – 4; CRI CA = Coping 
Responses Inventory Cognitive Avoidance Subscale; DAS = Dysfunctional Attitudes 
Scale. 
aAmong only those who were living with a spouse or partner (n = 66); 
Relationships of Demographic and Clinical Variables with Depressive 
Symptomatology 
 In order to determine if demographic and clinical variables were associated with 
depressive symptomatology, t-tests, ANOVAs, and correlational analyses were 
conducted (see Tables 6 and 7). No demographic variables were found to be related to 
depressive symptomatology (ps > .05). In contrast, two clinical variables were found to 
be related to depressive symptomatology. Those with a diagnosis of past Major 
Depressive Disorder reported greater depressive symptomatology (M = 19.31; SD = 
11.27) than those without a diagnosis of past Major Depressive Disorder (M = 13.60; SD 
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 = 7.48) (p = .02). Also, patients for whom more time had elapsed since their lung cancer 
diagnosis reported greater depressive symptomatology, r(93) = .20, p = .048.  
Table 6 
Relationships Between Depressive Symptomatology and Demographic Variables (N = 
95) 
Variable Depression (CES-D) p-value 
 Age (years) r = .05 .66 
 Gender (m, f) t = -1.0 .32 
 Education (< H.S., ≥ H.S.) t = -1.26 .21 
 Race (White, non-White) t = -1.57 .12 
 Ethnicity (Hispanic, non-Hispanic) t = -0.29 .77 
 Marital Status (married, not married) t = -0.29 .78 
 Total Household Income (< $40k, ≥ $40k) t = 0.71 .48 
 Alcohol Use in Past Month (yes, no) t = 0.28 .78 
 Cigarette Use (never, previous, current) F = 0.30 .75 
 Pack Years r = .01 .92 
aAmong only past smokers and current smokers (n = 83). 
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 Table 7 
Relationships Between Depressive Symptomatology and Clinical Variables (N = 95) 
 
Variable      Depression (CES-D) p-value 
 
  Diagnosis of Past Major Depression (yes, no) t = 2.37 .02 
 
  BMI r = .07 .52 
  
  Months Since Original Diagnosis r = .20 .05 
 
  Months Since Recurrencea r = -.01 .98 
 
  Disease Stage (II, III, IV) F = 0.23 .80 
 
  ECOG Performance Status (0, 1, 2-3) F = 0.71 .50 
 
  Surgery (yes, no) t = -0.40 .69 
 
  Months Since Surgeryb r = .23 .12 
 
  Radiation Therapy (never, previous, current) F = 0.98 .38 
 
  Months Since Radiation Therapyc r = .00 .98 
 
  Chemotherapy infusions for this course r = -.12 .24 
 
  Previous chemotherapy coursesd r = .07 .63 
  
  Antidepressant medication (yes, no) t = -0.42 .67 
 
Note: ECOG = Eastern Cooperative Oncology Group 
aAmong only those with a recurrence of Non-Small Cell Lung Cancer (n = 30); bAmong 
only those who had surgery; cAmong only those who received radiation therapy (n = 41); 
dAmong only those who received a course of chemotherapy previous to the current 
course (n = 45).
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Regression Analysis of Depressive Symptomatology 
 Based on the findings that perceived stigma was related to depressive 
symptomatology, a hierarchical regression analysis was conducted to determine if 
perceived stigma accounted for significant variability in scores on the CES-D above and 
beyond that accounted for by relevant variables (see Table 8). Diagnosis of past Major 
Depressive Disorder was specified for inclusion in the model prior to conducting 
analyses, time since original lung cancer diagnosis was included in the model because of 
its relationship with depressive symptomatology (see Table 7), and psychosocial 
variables were included based on the pre-specified model. As shown in Table 8, 
diagnosis of past Major Depressive Disorder accounted for 5% of the variance and time 
since original lung cancer diagnosis accounted for 4% of the variance in depressive 
symptomatology. Social support, avoidant coping, and dysfunctional attitudes were 
entered into the equation in the third step. Together, they accounted for an additional 35% 
of the variance in depressive symptomatology. Lastly, perceived stigma was entered into 
the model in the fourth step. It accounted for an additional 3% of the remaining variance 
in depressive symptomatology. As hypothesized, perceived stigma accounted for a 
statistically significant amount of additional variance in depressive symptomatology (p = 
.043). Together, these variables accounted for 47% of the variance in depressive 
symptomatology. 
 Table 8 
Summary of Hierarchical Regression Analysis for Variables Predicting Depressive 
Symtpomatology (CES-D) (N = 95) 
 Variable    β  ΔR2  
Step 1        .05 
 History of MDD   .25*   
Step 2        .04 
 Time Since Diagnosis   .11 
Step 3        .35 
 Social Support (ESSI)   -.11 
 Avoidant Coping (CRI CA)  .27** 
Dysfunctional Attitudes (DAS) .33** 
Step 4        .03 
Perceived Stigma (SIS)  .19* 
Note. Overall F (6, 88) = 12.43, p < .001; CES-D = Center for Epidemiologic Studies 
Depression Scale; MDD = Major Depressive Disorder; ESSI = ENRICHD Social Support 
Instrument; CRI CA = Coping Responses Inventory Cognitive Avoidance Subscale; DAS 
= Dysfunctional Attitudes Scale; SIS: Social Impact Scale.  
* p < .05, ** p < .01; 
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A second hierarchical regression analysis was conducted with a subset of the 
sample (n = 66) that was living with a spouse or partner and was eligible to complete the 
Dyadic Adjustment Scale – 4 (see Table 9). Diagnosis of past MDD was entered into the 
model in the first step and accounted for 8% of the variance in depressive 
symptomatology. Time since original lung cancer diagnosis was entered in the second 
step and accounted for an additional 5% of the variance. Social support, avoidant coping, 
dysfunctional attitudes, and dyadic adjustment were added in the third step and accounted 
for an additional 39% of variance. Perceived stigma was added in the fourth step and 
accounted for 4% of the remaining variance. As hypothesized, perceived stigma 
accounted for a statistically significant amount of additional variance in depressive 
symptomatology (p = .028). Together, these variables accounted for 56% of the variance 
in depressive symptomatology. 
 Table 9 
Summary of Hierarchical Regression Analysis for Variables Predicting Depressive 
Symtpomatology (CES-D) Among Participants Living With a Spouse or Partner (n = 66) 
 Variable    β  ΔR2  
Step 1        .08 
 History of MDD   .14*   
Step 2        .05 
 Time Since Diagnosis   .18 
Step 3        .39 
 Social Support (ESSI)   -.15 
 Avoidant Coping (CRI CA)  .11 
Dysfunctional Attitudes (DAS) .30** 
Dyadic Adjustment (DAS-4)   -.11 
Step 4        .04 
Perceived Stigma (SIS)  .24* 
Note. Overall F (7, 58) = 10.42, p < .001; CES-D = Center for Epidemiologic Studies 
Depression Scale; MDD = Major Depressive Disorder; ESSI = ENRICHD Social Support 
Instrument; CRI CA = Coping Responses Inventory Cognitive Avoidance Subscale; DAS 
= Dysfunctional Attitudes Scale; DAS-4 = Dyadic Adjustment Scale – 4; SIS = Social 
Impact Scale. 
* p < .05, ** p < .01 
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Additional hierarchical regression analyses were conducted to determine which 
components of perceived stigma contributed unique variance to depressive 
symptomatology. The Social Rejection and Internalized Shame subscales did not 
contribute significant variance to depressive symptomatology (ps ≥ .49); however, the 
Financial Insecurity and Social Isolation subscales did contribute significant variance to 
depressive symptomatology (see Tables 10 and 11). Similar trends were found, in 
analyses which included the Dyadic Adjustment Scale – 4 among the participants who 
were living with a spouse or partner (not shown). These findings suggest that financial 
insecurity and social isolation are the components of perceived stigma that may be most 
associated with depressive symptomatology. 
 Table 10 
Summary of Hierarchical Regression Analysis for Variables Predicting Depressive 
Symtpomatology (CES-D) (n = 95) 
 Variable    β  ΔR2  
Step 1        .05 
 History of MDD   .25**   
Step 2        .04 
 Time Since Diagnosis   .11 
Step 3        .35 
 Social Support (ESSI)   -.11 
 Avoidant Coping (CRI CA)  .25** 
Dysfunctional Attitudes (DAS) .37** 
Step 4        .03 
Financial Insecurity (SIS FinIns) .19* 
Note. Overall F (6, 88) = 12.53, p < .001; CES-D = Center for Epidemiologic Studies 
Depression Scale; MDD = Major Depressive Disorder; ESSI = ENRICHD Social Support 
Instrument; CRI CA = Coping Responses Inventory Cognitive Avoidance Subscale; DAS 
= Dysfunctional Attitudes Scale; DAS-4 = Dyadic Adjustment Scale – 4; SIS = Social 
Impact Scale. 
* p < .05, ** p < .01 
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 Table 11 
Summary of Hierarchical Regression Analysis for Variables Predicting Depressive 
Symtpomatology (CES-D) (n = 95) 
 Variable    β  ΔR2  
Step 1        .05 
 History of MDD   .22**   
Step 2        .04 
 Time Since Diagnosis   .08 
Step 3        .35 
 Social Support (ESSI)   -.10 
 Avoidant Coping (CRI CA)  .24** 
Dysfunctional Attitudes (DAS) .27** 
Step 4        .07 
Social Isolation (SIS SocIso)  .33** 
Note. Overall F (6, 88) = 12.53, p < .001; CES-D = Center for Epidemiologic Studies 
Depression Scale; MDD = Major Depressive Disorder; ESSI = ENRICHD Social Support 
Instrument; CRI CA = Coping Responses Inventory Cognitive Avoidance Subscale; DAS 
= Dysfunctional Attitudes Scale; DAS-4 = Dyadic Adjustment Scale – 4; SIS = Social 
Impact Scale. 
* p < .05, ** p < .01 
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Relationships of Demographic and Clinical Variables with Perceived Stigma 
 In order to determine if demographic and clinical variables were associated with 
perceived stigma, t-tests, ANOVAs, and correlational analyses were conducted (see 
Tables 12 and 13). Age was associated with perceived stigma, such that younger patients 
reported greater perceived stigma. Also, those who reported no alcohol use in the past 
month (M = 45.19, SD = 11.30) reported greater perceived stigma than those who 
reported using alcohol in the past month (M = 40.00, SD = 12.06). In addition, patients 
with a diagnosis of past Major Depressive Disorder (M = 48.91, SD = 12.71) as well as 
those with an ECOG performance status of 2 or 3 (M = 50.63, SD = 12.70) reported 
greater perceived stigma as compared to those without a history of Major Depressive 
Disorder (M = 41.86, SD = 11.48) and those with performance statuses of 0 (M = 40.69, 
SD = 10.35) or 1 (M = 41.99, SD = 11.70). 
Although no hypotheses were offered, multivariate stepwise analyses were 
conducted to determine which of these demographic and clinical variables contributed 
significant variance in perceived stigma (see Table 14). Age and performance status were 
the only variables that contributed significant variance in perceived stigma above and 
beyond that contributed by one another.
 Table 12 
Relationships Between Perceived Stigma and Demographic Variables (N = 95) 
Variable Perceived Stigma (SIS) p-value 
 Age (years) r = -.21 .04 
 Gender (m, f) t = 1.14 .26 
 Education (< H.S., ≥ H.S.) t = -1.01 .32 
 Race (White, non-White)  t = -1.19 .24 
 Ethnicity (Hispanic, non-Hispanic) t = 0.38 .71 
 Marital Status (married, not married) t = 0.95 .35 
 Total Household Income (< $40k, ≥ $40k) t = 0.68 .50 
 Alcohol Use in Past Month (yes, no) t = 2.16 .03 
 Cigarette Use (never, previous, current) F = 0.23 .80 
 Pack Years r = .18 .08 
aAmong only past smokers and current smokers (n = 83). 
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 Table 13 
Relationships Between Perceived Stigma and Clinical Variables (N = 95) 
Variable      Perceived Stigma (SIS) p-value 
 
  Diagnosis of Past Major Depression (yes, no) t = 2.09 .04 
 
  BMI r = -.15 .14 
  
  Months Since Original Diagnosis r = .12 .25 
 
  Months Since Recurrencea r = .02 .91 
 
  Disease Stage (II, III, IV) F = 0.63 .54 
 
  ECOG Performance Status (0, 1, 2-3) F = 3.46 .04 
 
  Surgery (yes, no) t = -0.60 .55 
 
  Months Since Surgeryb r = .12 .45 
 
  Radiation Therapy (never, previous, current) F = 0.08 .92 
 
  Months Since Radiation Therapyc r = .05 .74 
 
  Chemotherapy infusions for this course r = .02 .85 
 
  Previous chemotherapy coursesd r = .17 .26 
  
  Antidepressant medication (yes, no) t =1.38 .17 
 
Note: ECOG = Eastern Cooperative Oncology Group 
aAmong only those with a recurrence of Non-Small Cell Lung Cancer (n = 30); bAmong 
only those who had surgery; cAmong only those who received radiation therapy (n = 41); 
dAmong only those who received a course of chemotherapy previous to the current 
course (n = 45). 
 
39 
  
Table 14 
Summary of Stepwise Regression Analysis for Variables Predicting Perceived Stigma 
(SIS) (n = 95) 
 Variable     β  ΔR2  
Step 1         .05 
 ECOG Performance Status (0, 1, 2-3) .22*   
Step 2         .05 
 Age      -.22* 
 
Note. Overall F (2, 92) = 4.94, p < .01; SIS = Social Impact Scale; ECOG = Eastern 
Cooperative Oncology Group. 
* p < .05
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 Mediational Analyses 
 In order to determine which psychosocial variables would be tested for mediation 
of the relationship between perceived stigma and depressive symptomatology, 
correlational analyses were conducted between perceived stigma and social support, 
avoidant coping, dysfunctional attitudes, and dyadic adjustment (see Table 10). Social 
support, dysfunctional attitudes, and dyadic adjustment were all significantly correlated 
with perceived stigma (ps < .01); avoidant coping was not (p = .45). Thus, three separate 
mediational analyses were conducted to determine if social support, dysfunctional 
attitudes, or dyadic adjustment mediated the relationship observed between perceived 
stigma and depressive symptomatology. The method described by MacKinnon, et al. 
(2007) was employed to determine if there is a direct effect (c) between the predictor and 
dependent variable which is mediated by the proposed mediator. 
Table 15 
Correlations Between Perceived Stigma and Psychosocial Variables (N = 95) 
Variable Perceived Stigma (SIS) p-value 
Social Support (ESSI) -.35  .001 
Dyadic Adjustment (DAS-4)a -.35 .004 
Avoidant Coping (CRI CA) .08  .450 
Dysfunctional Attitudes (DAS) .43 < .001 
aAmong only those living with a spouse or partner (n = 66). 
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  The first model tested whether social support mediated the relationship of 
perceived stigma to depressive symptomatology. Perceived stigma was a significant 
predictor of depressive symptomatology (B = .32, p < .001) as well as social support (B = 
-.09, p < .001). After controlling for social support, there was a reduction in the 
regression coefficient for perceived stigma (B = .28, p < .001), indicating that the effect 
of perceived stigma on depressive symptomatology was partially mediated by social 
support; however, the Sobel test was only marginally significant (z = 1.70, p = .089), 
suggesting no mediational relationship (see Figure 3). 
Social Support 
(ESSI) 
Perceived Stigma 
(SIS) 
Depressive 
Symptomatology 
(CES-D) 
B = -.53* 
B = .32** (B = .28**) 
B = -.09** 
 
Figure 3. Proposed Model of Social Support (ESSI) as a Mediator Between Perceived 
Stigma (SIS) and Depressive Symptomatology (CES-D). ESSI: ENRICHD Social 
Support Instrument; SIS: Social Impact Scale; CES-D: Center for Epidemiologic Studies 
Depression Scale; Sobel test z = 1.70, p = .089. 
*p < .05, **p < .01 
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 The second model tested whether dyadic adjustment mediated the relationship of 
perceived stigma to depressive symptomatology. Perceived stigma was a significant 
predictor of depressive symptomatology, B = .40, p < .001, as well as dyadic adjustment, 
B = -.10, p = .005. After controlling for dyadic adjustment, there was a reduction in the 
 regression coefficient for perceived stigma to B = .28, p < .001, indicating that the effect 
of perceived stigma on depressive symptomatology was partially mediated by dyadic 
adjustment. Sobel’s test was significant (z = 2.10, p = .036), adding further support to the 
mediation model (see Figure 4). 
Dyadic 
Adjustment 
(DAS-4) 
Perceived Stigma 
(SIS) 
Depressive 
Symptomatology 
(CES-D) 
B = .40** (B = .32**) 
B = -.80** B = -.10** 
 
Figure 4. Proposed Model of Dyadic Adjustment (DAS-4) as a Mediator Between 
Perceived Stigma (SIS) and Depressive Symptomatology (CES-D) aAmong only those 
participants who were living with a spouse or partner (n = 66); DAS-4 = Dyadic 
Adjustment Scale-4; SIS = Social Impact Scale; CES-D = Center for Epidemiologic 
Studies Depression Scale; Sobel test z = 2.10, p = .036. 
*p < .05, **p < .01 
 
The third model tested whether dysfunctional attitudes mediated the relationship 
of perceived stigma to depressive symptomatology. Perceived stigma was a significant 
predictor of depressive symptomatology, B = .32, p < .001, as well as dysfunctional 
attitudes, B = .94, p < .001. After controlling for dysfunctional attitudes, there was a 
reduction in the regression coefficient for perceived stigma to B = .22, p < .001, 
indicating that the effect of perceived stigma on depressive symptomatology was partially 
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 mediated by dysfunctional attitudes. Sobel’s test was significant (z = 2.82, p = .005), 
adding further support to the mediation model (see Figure 5). 
 
  
Dysfunctional 
Attitudes (DAS) 
Perceived Stigma 
(SIS) 
Depressive 
Symptomatology 
(CES-D) 
B = .32** (B = .22**) 
B = .11** B = .94** 
 
Figure 5. Proposed Models of Dysfunctional Attitudes (DAS) as a Mediator Between 
Perceived Stigma (SIS) and Depressive Symptomatology (CES-D). DAS = Dysfunctional 
Attitudes Scale; SIS = Social Impact Scale; CES-D = Center for Epidemiologic Studies 
Depression Scale; Sobel test z = 2.82, p = .005. 
*p < .05, **p < .01 
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Discussion 
Summary of Results  
The primary aim of this study was to examine the relationship between perceived 
stigma and depressive symptomatology in people with lung cancer. The study also sought 
to examine relationships between several psychosocial factors that are related to 
depressive symptomatology in other populations and depressive symptomatology in 
people with lung cancer. Additionally, it aimed to determine if perceived stigma accounts 
for variability in depressive symptomatology in lung cancer patients above and beyond 
that explained by psychosocial factors that have been found to be related to depressive 
symptomatology in other populations. Lastly, this study sought to determine whether the 
psychosocial factors assessed mediated the relationship between perceived stigma and 
depressive symptomatology.  
Results generally supported the study hypotheses. As expected, greater perceived 
stigma was significantly related to higher levels of depressive symptomatology. More 
avoidant coping, poorer social support, poorer dyadic adjustment, and more dysfunctional 
attitudes were also significantly related to greater depressive symptomatology. Additional 
analyses indicated that perceived stigma contributed unique variance in depressive 
symptomatology above and beyond that accounted for by clinical (time since lung cancer 
diagnosis), demographic (history of past Major Depressive Disorder), and psychosocial 
(avoidant coping, social support, dyadic adjustment, and dysfunctional attitudes) factors. 
Further analyses showed that financial insecurity and social isolation may be the aspects 
of perceived stigma that most contribute to depressive symptomatology. In addition, 
younger patients, those who reported no alcohol use in the past month, those with a 
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history of Major Depressive Disorder, as well as those with poorer performance statuses 
reported greater perceived stigma; however, only age and performance status contributed 
significant variance to perceived stigma. Finally, analyses suggested that dyadic 
adjustment and dysfunctional attitudes mediated the relationship between perceived 
stigma and depressive symptomatology. The following discussion will consider the 
theoretical and clinical implications of these findings, describe the study’s limitations, 
and identify future research directions suggested by the study findings.   
Theoretical and Clinical Implications 
As can best be determined, this is the first study to examine the relationship of 
perceived stigma to depressive symptomatology in lung cancer patients. This study’s 
findings provide quantitative evidence consistent with the qualitative evidence provided 
by Chapple and colleagues (2004) which suggested that lung cancer patients experience 
significant stigma from others as a result of their illness. Moreover, this study extends 
this finding to provide evidence for a link between perceived stigma and depressive 
symptomatology as well as possible mediators of this relationship.  
Documenting this link among lung cancer patients is important for several 
reasons.  First, it adds further evidence to the growing body of literature suggesting a 
connection between illness-related stigma and depressive symptomatology. As noted 
earlier, studies have found that patients with other stigmatizing conditions (e.g., HIV 
infection) who report more stigma also report greater depressive symptomatology 
(Simbayi, et al., 2007). Second, it adds to knowledge about the possible etiology of 
depressive symptomatology among lung cancer patients, a group that is particularly likely 
to experience depressive symptoms (Buccheri, 1998; Nakaya et al., 2006).  
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This study’s findings are consistent with the Cognitive Theory of Depression, 
which states that one’s experiences may contribute to depressive symptomatology by 
activating maladaptive schemas, or ways of thinking, from past experiences that are 
related to the current situation (Beck & Dempster, 1976; Beck, Rush, Shaw, & Emery, 
1979). When activated, these maladaptive schemas begin to perpetuate dysfunctional 
attitudes, or faulty reasoning, within the individual that are evident in their automatic 
cognitive responses to stimuli. These automatic cognitive responses propagate negative 
views of oneself, the experiences one undergoes, and one’s outlook on the future. These 
negative thought patterns, the Cognitive Triad, are the most conscious manifestations of 
the depressive state and are theorized to result in affective and somatic depressive 
symptoms (Beck et al., 1979). This study’s findings suggest that this chain reaction could 
be activated in lung cancer patients who perceive they are being stigmatized because of 
their illness. Some lung cancer patients may in fact misperceive that they are being 
stigmatized because of their illness; however, the effect of misperceived stigma would 
likely be similar to that of actual stigmatization. Consider, Beck and colleagues’ 
explanation of the effects of misperceiving being rejected and socially alienated – two 
expressions of stigma: 
“For example, if the patient incorrectly thinks he is being rejected, he will react 
with the same negative affect (for example, sadness, anger) that occurs with actual 
rejection. If he erroneously believes he is a social outcast, he will feel lonely” 
(Beck et al., 1979, p. 11). 
The finding that those experiencing more stigma also reported greater depressive 
symptomatology provides evidence that this process may be under way in some patients 
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with lung cancer, an illness for which patients are often stigmatized (Chapple et al., 
2004). Moreover, this study also suggested mechanisms by which stigma may contribute 
to depression in lung cancer patients. Specifically, the mediational effect of dysfunctional 
attitudes on the relationship between perceived stigma and depressive symptomatology 
further suggest that Beck’s Cognitive Theory of Depression may help explain the 
etiology of depressive symptoms often experienced by lung cancer patients.  
The mediational effects of dyadic adjustment on the relationship between 
perceived stigma and depressive symptomatology also suggest additional pathways 
through which perceived stigma may lead to or worsen the severity of depressive 
symptoms. That is, greater perceived stigma may activate the process which leads to 
relational problems with close others which, in turn, might worsen one’s depressive 
symptoms. Research in the general population, as well as in chronically-ill populations, 
has shown that individuals experiencing poorer dyadic adjustment (Berger et al., 2001; 
Miles et al., 1997; Simbayi et al., 2007) report greater depressive symptomatology.  
 With regard to clinical implications, the findings suggest psychotherapeutic 
approaches that might be employed to alleviate or prevent depressive symptoms among 
lung cancer patients. Most approaches to reducing stigma are focused on reducing the 
stigma that individuals feel towards people of another group (Couture & Penn, 2003). 
They are either protests against the injustice of stigmatizing behavior or programs to 
educate the public about inaccuracies of stereotypes and replace these inaccuracies with 
facts (Corrigan, Kerr, & Knudsen, 2005). These approaches do not seem very applicable 
to reducing perceived stigma in lung cancer patients.  However, other approaches such as 
cognitive therapy may be helpful in counteracting the effects of stigma (e.g., 
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dysfunctional attitudes) on the stigmatized individual (Corrigan et al., 2005).  
Specifically, a modified cognitive therapy approach targeted at altering thoughts and 
feelings associated with perceived stigma may prove effective in reducing depressive 
symptomatology.   
 Self-blame is an important component of perceived stigma that warrants attention. 
One strategy might involve pointing out to patients that, although it is true that smoking 
causes many cases of lung cancer, self-blame is a maladaptive coping strategy after lung 
cancer is diagnosed. To help patients move beyond the self-blame they may experience as 
a result of perceived stigma, they might be encouraged to present exempting beliefs. For 
example, not everyone who smokes gets cancer and not everyone who gets cancer 
smoked. Thus, it is impossible to ascertain whether one’s lung cancer diagnosis can be 
directly attributable to their smoking. Knowing that one may not necessarily have 
“caused” their cancer might help reduce self-blame. The addictiveness of cigarette 
smoking and the deception in early tobacco industry advertisements could also be 
understood by some patients to put them in the position of having been wronged rather 
than being a wrong-doer. Though self-blame can be targeted and reduced, it may remain 
in some patients. Those patients should be encouraged to acknowledge the potential for 
culpability, then move on to more productive uses of their energies. To help facilitate 
this, a psychotherapeutic approach should assist lung cancer patients with helping their 
families cope with their illness and its present and future consequences. Patients could 
also be offered counseling to aid in their understanding of their illness and their 
oncologists’ recommended treatment plan. These and other focuses within the broader 
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framework of Cognitive Therapy for depression could help patients move past self-blame 
and other consequences of their illness.  
Limitations 
 This study had several limitations. First, the cross-sectional nature of this study 
limits the conclusions that can be drawn from its findings. Although the results can be 
interpreted as suggesting that stigma contributes to depression, the possibility that 
depression contributes to stigma cannot be ruled out.  The use of a longitudinal design 
would allow the testing of temporal hypotheses. Second, the study’s sample was 
relatively homogenous with respect to race and ethnicity, which limits the ability to 
generalize to the broader lung cancer patient population. Third, the lung cancer patients 
in this study were receiving chemotherapy designed to extend life; thus, this study’s 
findings may not generalize to lung cancer patients receiving other types of treatments or 
receiving no treatment at all. Lastly, although use of antidepressant medication was not 
related to depressive symptomatology in this study, participants’ use of psychotherapy 
and related services was not assessed. 
Future Directions  
 Because this is the first quantitative study to identify the relationship between 
perceived stigma and depressive symptomatology among lung cancer patients, it will be 
important to see if these findings can be replicated in future research.  Beyond this, there 
is a need for longitudinal research that would allow for examination of the temporal 
relationships between perceptions of stigma and depressive symptomatology.  
Based on the findings that psychosocial factors mediate the relationship between 
perceived stigma and depressive symptomatology, longitudinal study designs should be 
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employed in future studies. These designs would enable examinations of temporal 
relationships and would allow stronger causal inferences to be drawn. Also, future studies 
should examine the potential relationship between the use of psychotherapy services and 
depressive symptomatology. Future studies should also aim to recruit samples of lung 
cancer patients that are more diverse with regard to race, ethnicity, and socioeconomic 
status. Additionally, the use of interventions to reduce depressive symptomatology 
among lung cancer patients and other stigmatized groups should consider targeting 
stigma and its direct effects. 
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